Plain-English translation of NCT06446960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a stroke, some people develop chronic pain in their limbs that can be difficult to treat. This trial is testing whether injections of local anesthetics—specifically lidocaine or levobupivacaine—delivered directly around nerves can reduce this pain. Researchers will compare these two medications against placebo (salt water) to see which works best.
Post-stroke pain can be severe and resistant to standard pain medications. This trial is exploring whether blocking nerve signals with local anesthetics might offer relief when other treatments haven't worked.
You likely qualify if…
You likely don't qualify if…
You will receive two injections (called nerve blocks) given 2 weeks apart. An anesthesiologist will administer the injection around the nerve that controls pain in your affected limb. You'll be assessed immediately after the injection, then again at 45 minutes and 5 hours. After each injection, you'll track your pain daily for 2 weeks using a diary. The entire study lasts about one month from start to finish.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
France
Phase
Large-scale testing
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment target
~36 participants
Started
February 2024
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
VALERIA MARTINEZ, MD
Institut National de la Santé Et de la Recherche Médicale, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.